

16 October 2026

ASX Announcement

Nasodine Nasal Spray Approved in the Philippines

Firebrick Pharma Limited (ASX: FRE) (the **Company** or **Firebrick**) is pleased to announce that Nasodine Nasal Spray (“Nasodine”) has been approved for marketing in the Philippines.

SV More Corporation (“**SV More**”), the Company’s Philippines licensing partner, has advised that they have received formal notification that Nasodine Nasal Spray had been approved by the Philippines Food and Drug Administration (“PFDA”).

A copy of the Certificate of Product Registration (“CPR”) from the PFDA has been provided to Firebrick. It states that Nasodine Nasal Spray conformed with the requirements and standards for marketing authorisation of pharmaceutical products and has been approved as an antiseptic within the Over-the-Counter (OTC) Drug class.

The approved packaging describes the product as “nasal antiseptic designed to help reduce bacteria, viruses and fungi in the nose.”

The uses on the approved label are stated as:

- When you have a nasal infection
- After exposure to likely sources of respiratory infections, especially in crowded settings
- When you have cold or flu-like symptoms to help reduce the spread of infection to family, friends and coworkers, especially in crowded places

The approval is subject to SV More meeting standard post-approval documentary requirements. The initial approval is valid until 24 September 2028 and thereafter subject to revalidation based on post-approval compliance with the requirements of the CPR.

“This is a long-awaited and incredibly important milestone for Firebrick and our licensing partner and strategic investor, SV More,” said Firebrick Executive Chairman, Dr Peter Molloy. “It is also our first approval of Nasodine within the OTC Drug category, which could be very useful in other jurisdictions. We will be working closely with SV More over the next few months to prepare for the product launch, which could occur as early as Q1 CY2027.”

The Philippines is a sophisticated pharmaceutical market with a population of approx. 116 million people, making it the second largest market in Southeast Asia.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -



About Firebrick Pharma

Firebrick Pharma is developing and commercialising novel consumer health products based on povidone-iodine (PVP-I). Firebrick's first product, Nasodine® Nasal Spray (0.5% PVP-I), has been launched in the United States, Singapore, and Fiji. In March 2026, Firebrick announced that Nasodine Nasal Spray had been approved for marketing in Indonesia. In October 2026, Firebrick announced the approval in the Philippines, bringing the total number of countries where it can be sold to five. The Company also announced the expansion of US marketing to include the US retail market. Firebrick is building a portfolio of Nasodine products and in January 2026 announced the launch of its second product, Nasodine Throat Spray, in Singapore and Fiji. Further new Nasodine-brand products are planned during FY27. For further information, visit firebrickpharma.com

Contacts:

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com